1Langer CJ, Mok T,Postmus PE. Targeted agents in thethird-/fourth-line treatment of patients with advanced(stage IH/IV ) non-small cell lung cancer ( NSCLC )[J]. Cancer Treat Rev,2013,39(3) :252-260.
2Hirsh V. Afatinib ( BIBW 2992) development in non-small-cell lung cancer[ J]. Future Oncol,2011,7(7):817 -825.
3Kim SM, Kwon OJ , Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance toirreversible EGFR inhibitors in non-small cell lung cancerwith T790M resistance mutation[ J]. Mol Cancer Ther,2012,11(10) :2254 -2264.
4Kwak E. The role of irreversible HER family inhibition inthe treatment of patients with non-small cell lung cancer[J]. Oncologist, 2011,16(11) :1498 -1507.
5Rolfo C , Giovannetti E, Hong DS, et al. Novel therapeu-tic strategies for patients with NSCLC that do not respondto treatment with EGFR inhibitors [ J ]. Cancer Treat Rev,2014,40(8) :990-1004.
6Hirsh V,Cadranel J,Cong XJ, et al. Symptom and quali-ty of life benefit of afatinib in advanced non-small-celllung cancer patients previously treated with erlotinib orgefitinib results of a randomized phase II b/III trial(LUX-Lung 1) [J]. J Thorac Oncol, 2013,8 (2) ;229-237.
7Yang JC, Shih JY, Su WC, et al. Afatinib for patientswith lung adenocarcinoma and epidermal growth factor re-ceptor mutations ( LUX-Lung 2 ) : a phase 2 trial [ J ].Lancet Oncol,2012,13(5) :539 -548.
8Kato T, Yoshioka H,Okamoto I,et al. Afatinib versuscisplatin plus pemetrexed in Japanese patients with ad-vanced non-small cell lung cancer harboring activatingEGFR mutations: Subgroup analysis of LUX-Lung 3 [ J].Cancer Sci, 2015,106(9) :1202 -1211.
9Katakami N, Atagi S,Goto K, et al. LUX-Lung 4 : Aphase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treat-ment with erlotinib, gefitinib, or both [ J ]. J Clin Oncol,2013,31(27):3335 -3341.
10Schuler M,Yang JC, Park K,et al. Afatinib beyondprogression in patients with non-small-cell lung cancerfollowing chemotherapy, erlotinib/gefitinib and afatinib :phase HI randomized LUX-Lung 5 trial[ J]. Ann Oncol,2016,27(3) :417 -423.
